Skip to content

    Stendra Dosing

    Created by
    specmu1979
    specmu1979

    Use code SFKSFJK10 at checkout HERE: https://easypharm.space/Stendra

    Stendra Dosing

    Patients recovered with supportive care following withdrawal of ustekinumab. The safety of STELARA in combination with other biologic immunosuppressive agents or phototherapy was not evaluated in clinical studies of psoriasis. In Crohn s disease induction studies, common adverse reactions 3 or more of patients treated with STELARA and higher than placebo reported through Week 8 for STELARA 6 mg kg intravenous single infusion or placebo included vomiting 4 vs 3. All patients receiving STELARA , especially those 60 years or those with a history of PUVA or prolonged immunosuppressant treatment, should be monitored for the appearance of NMSC. If diagnosis is confirmed, discontinue STELARA and institute appropriate treatment. The safety of STELARA has not been evaluated in patients who have a history of malignancy or who have a known malignancy. Cases of interstitial pneumonia, eosinophilic pneumonia

    Preview